Heart Failure Therapeutics in Asia-Pacific Markets to 2024-Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy
Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality. There are more than 26 million people with HF globally and this is increasing because of the rapidly aging population. HF is a major global healthcare problem as the number of HF patients is increasing. It has the greatest negative impact on quality of life compared with other major chronic disease, such as diabetes, arthritis, and hypertension. HF has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles. Increasing risk factors will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth. Despite therapeutic advances, the morbidity and mortality associated with HF continues to be considerable, particularly in elderly patients. Get Sample PDF of " Heart Failure Therapeutics in Asia-Pacific Markets" Report@ https://www.premiummarketinsights.c...